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Exploring structural differences between antagonistic peptides for the
development of orally bioavailable PCSK9 inhibitors
PDB File: 6U3I Chain A and B, 5VLP Chain D: LDLR antagonist peptide
Primary Citations:
Burdick, D. J., Skelton, N. J., Ultsch, M., Beresini, M. H., Eigenbrot, C., Li, W., Zhang, Y., Nguyen, H.,
Kong-Beltran, M., Quinn, J. G., & Kirchhofer, D. (2020). Design of organo-peptides as bipartite
PCSK9 antagonists. ACS Chemical Biology, 15(2), 425–436.
https://doi.org/10.1021/acschembio.9b00899
Zhang, Y., Ultsch, M., Skelton, N. J., Burdick, D. J., Beresini, M. H., Li, W., Kong-Beltran, M.,
Peterson, A., Quinn, J., Chiu, C., Wu, Y., Shia, S., Moran, P., Di Lello, P., Eigenbrot, C., &
Kirchhofer, D. (2017). Discovery of a cryptic peptide-binding site on PCSK9 and design of
antagonists. Nature Structural & Molecular Biology, 24(10), 848–856.
https://doi.org/10.1038/nsmb.3453
Description:
Familial hypercholesterolemia (FH) is an autosomal genetic disease which causes elevated blood
levels of low-density lipoprotein (LDL). One of the main causes of FH is gain-of-function mutations in the
gene coding for PCSK9 (proprotein convertase subtilisin/kexin type 9). The PCSK9 protein binds to lowdensity lipoprotein receptors (LDLR) on the surface of hepatocytes and promotes their degradation,
preventing recycling of LDLRs and thus increasing LDL blood levels. PCSK9 inhibitors, a class of FH drugs,
are injectable prescriptions containing monoclonal antibody therapies that bind to PCSK9 inhibiting LDLR
binding. Orally bioavailable medications can be developed using small-molecule-peptide inhibitor strategies
in a cryptic site (N-terminal groove) adjacent to the EGF(A) binding site located in the catalytic domain
(Zhang et al., 2017). This groove contains a P’ helix region (S153-I161) with conformational flexibility leaving
the site open to small-molecule peptides. Fab7G7 acts as the crystallization chaperone (binds to the second
module (M2) of the C-terminal domain) by instigating the conformational change. The peptide must contain
two components: a P’ helix like peptide with high binding affinity and an extension with antagonistic
properties to inhibit LDLR binding. The extension must encroach upon the EGF(A) binding site’s hydrophobic
pocket, a significant contributor to EGF(A)’s binding energy. Bipartite inhibitors with organic moieties
attached to the peptide core were found to have potent antagonistic activity and high binding affinity (Burdick
et all., 2020).
Specific Model Details:
There are two peptides and one active site. 6U3I and 5VLP, each, contain a different peptide
which binds to the N-terminal groove of the catalytic domain of PCSK9. The binding site (shown in Model A.
View 1) is derived from 6U3I. The binding site, peptide A, and peptide B contain magnets to show the
structural interactions. Peptide A and Peptide B will both be removable from the binding site.

Peptide A

Peptide B

Model A. View 1: No
peptide attached

Model A. View 2:
Peptide A attached

Model A. View 3:
Peptide B attached

Significant Interactions between PCSK9 and Peptides A and Peptide B
Interaction (color
Residues
Explanation
noted on model)
1 (lightpink)
PCSK9: Asp343
The L-homoarginine substitution from L-arginine
Peptide A: hArg5
improved binding affinity through the formation of a
Peptide B: hArg5
new salt bridge interaction by the side chain guanidium
group and the Asp343 residue on PCSK9.
2 (plum/purple)
PCSK9: Val241, Ile395
The binding of isoleucine to the extremely hydrophobic
Peptide A: Ile6
region on PCSK9 (Val241 and Ile395) increased
Peptide B: Ile6
binding affinity due to van der Waals contact.
3 (indianred)
PCSK9: Ala341, Pro364,
Integrating tryptophan as the vector choice was
Glu366, Asp367
confirmed by 1) the van der Waals interactions with
Peptide A: Trp1
Ala341 and Pro364, and 2) the hydrogen bonding
Peptide B: Trp1
between tryptophan’s indole and the backbone
carbonyls of Glu366 and Asp367.
4 (lightgreen)
PCSK9: Ile369, Phe379,
The PCSK9 contact residues were seen to interact
Asp238, Ala239
with the organic moiety of peptide B, intruding in the
Peptide A: N/A
hydrophobic pocket of the EGF(A) binding region. This
Peptide B: 1-aminopocket is a significant contributor to EGF(A)’s binding
phenylcyclohexane-1energy. This interaction led to the inhibition of PCSK9.
carbonyl*
*Colored cpk to show hydrophobic functional group of the organic moiety
Some important residues are highlighted on the model as well. (1) In khaki/yellow, the fourth residue (val4 in
peptide A and lys4 in peptide B) in the peptide core was found to be a surface-exposed residue instead of a
contact residue, making lysine the best substitution with increased binding affinity. (2) In coral/orange, the
gly7 (peptide A) to d-Ser7 (peptide B) substitution is highlighted. This D-serine substitution favored the
required positive φ backbone dihedral angle and further assisted in positioning the lysine residues
downstream. This change resulted in a 2-3-fold gain in affinity. (3) Phe-2, Pro-1, Gly0 (FPG motif) in peptide
A is colored turquoise. Initially it was thought that the FPG motif and the anchor (tryp1) made a beta-turn
causing the proline 5 residue to extend into the EGF(A) binding site, creating steric clash. Instead, with
further modeling and experimentation, it was shown to preclude further extension.

